HemaSphere Podcast

HemaSphere Podcast

HemaSphere Journal
Country USA
Language EN
Episodes 26
Latest 16.11.2026

HemaSphere is the official online, open access journal of the European Hematology Association (EHA). The podcast series features host and guest speakers discussing select HemaSphere publications, offering casual and insightful conversations about hematology research. Listeners can hear the stories behind the papers and stay updated on basic, translational, and clinical research in hematology.

Episodes

  • When Treatment Works, but the Numbers Don't - Pierre Sujobert
    When Treatment Works, but the Numbers Don't - Pierre Sujobert 16.11.2026 29m
    This episode examines the gap between improving survival and continuing disease burden in hematological malignancies. Dr Pierre Sujobert discusses with host Dr Charles de Bock epidemiological patterns across hematological malignancies, including rising incidence in multiple myeloma, non-Hodgkin lymphomas, and acute myeloid leukemia. He also considers environmental and occupational exposures, the value of locally focused research, and the importance of taking patients’ work histories seriously.This episode is relevant to hematology researchers and clinicians studying treatment outcomes, prevent...
  • CAR T From Within - Vilcot, Brugère, Fuentealba, Houot
    CAR T From Within - Vilcot, Brugère, Fuentealba, Houot 21.10.2026 39m
    Could making CAR T cells directly inside the patient change how treatment is delivered? Scientific Editor Dr Charles De Bock joins Prof Roch Houot, Dr Jaime Fuentealba, François Vilcot, PharmD, and Carole-Anne Brugère, PharmD, to explore the promise and challenges of in vivo CAR therapy. They compare delivery approaches, examine safety and targeting, and discuss potential gains in access alongside uncertainty over costs. Listen for a multidisciplinary perspective on what comes next.Read the referenced Review Article here: https://bit.ly/4d1mfjPKey topicsHow in vivo CAR therapy differs from con...
  • Why More Mitochondrial DNA Mutations Can Mean a Better Outcome - Dr Ilaria Pagani
    Why More Mitochondrial DNA Mutations Can Mean a Better Outcome - Dr Ilaria Pagani 10.09.2026 40m
    This episode explores how chronic myeloid leukemia has been transformed by imatinib and other TKIs, while also showing why major clinical challenges remain for the patients who do not respond well or want to stop therapy. Host Scientific Editor Dr Charles de Bock talks with Dr. Ilaria Pagani about her recent HemaSphere paper on mitochondrial DNA mutations, oxidative phosphorylation, and treatment response in CML, and why mitochondria may be an overlooked source of biomarkers and new targets. We discuss the biology of relapse, why some patients can achieve treatment-free remission, and how mito...
  • Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel
    Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel 17.06.2026 38m
    In this episode, host Dr Charles de Bock delves into groundbreaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in MDS with Dr Manja Wobus and Dr Katja Sockel. Join us as we unpack the mechanisms, animal studies, and future clinical prospects for this promising therapy.Read the accompanying article published in HemaSphere https://bit.ly/3OjuuiSi4MDS, EHA's Specialized Working Group information https://hsphere.pub/5d4
  • p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór
    p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór 07.05.2026 36m
    Discover the latest insights into the multifaceted role of p53 in normal hematopoiesis and its critical involvement in myeloproliferative neoplasms (MPNs). This episode features Dr. Isabelle Plo and Dr. Barbara Monte-Mór sharing their expertise on TP53 mutations, molecular mechanisms driving leukemic transformation, and emerging therapeutic strategies targeting p53.Article: https://bit.ly/4sZbo01Comments, Suggestions or Feedback? Please take a few minutes and let us know: https://wkf.ms/4pDYjYb
  • Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
    Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood 09.02.2026 46m
    In this episode, host HemaSphere Scientific Editor Dr Charley de Bock speaks with Associate Professor Dr Matthew Greenwood about the SUBLIME (ALL09) trial, which explores replacing consolidation chemotherapy with blinatumomab in adolescents and young adults with B‑cell ALL. They discuss why immunotherapy may outperform traditional cytotoxic approaches, how MRD‑guided treatment is reshaping risk stratification, and what future protocols might look like as genomic and immune‑response data are integrated in real time. Dr. Greenwood also shares upcoming innovations—including menin inhibitors, vene...
  • Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate
    Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate 02.12.2025 55m
    In this extended episode of the HemaSphere podcast, based on a must-read Perspective "Can health inequalities in sickle cell disease be addressed through novel therapies?", our host Scientific Editor Charles de Bock discusses sickle cell disease with co-authors, covering both expert and lived-patient perspectives. They explore the complexities of living with the disease, the current treatment landscape, and highlight the ongoing health inequalities faced by patients, the impact of withdrawn therapies, and the need for improved communication and trust between patients and healthcare providers.F...
  • Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD
    Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD 03.11.2025 35m
    Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD, join Dr. Charles de Bock to unpack the challenges of diagnosing and treating acute leukemias of ambiguous lineage (ALAL). Discover how RNA sequencing, machine learning, and collaboration are shaping the future of precision medicine in hematology. 🎧 Listen and then read the full open-access article on the HemaSphere website https://bit.ly/4oeJo6w
  • EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski
    EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski 01.10.2025 40m
    Join our host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski, first author of this 2025 HemaSphere Top Cited –Clinical Award-winning paper. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities and the need for a structured grading system.EHA/EBMT Survey on Grading and Management of ICAHT, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube. Listen and enjoy casual, insightful discussions about #hematology research.You can find the referenced article, in fu...
  • Tackling NUP98 Rearranged AML in Pediatric Oncology - Prof Michel Zwaan, Prof Olaf Heidenreich
    Tackling NUP98 Rearranged AML in Pediatric Oncology - Prof Michel Zwaan, Prof Olaf Heidenreich 01.09.2025 41m
    Host Dr Charles de Bock speaks with Prof Michel Zwaan and Prof Olaf Heidenreich, co-authors from the 2025 HemaSphere Award - Top Cited: Biology paper, "The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML." The conversation delves into the complexities of #AML, particularly focusing on NUP98 rearranged AML and the therapeutic potential of Menin inhibitors. The discussion highlights the challenges in treating this aggressive form of leukemia, the mechanisms of menin inhibitors, and the importance of combining therapies to improve patient outcomes. Season 3, Episode 5...
  • Part 2 - Metabolism in hematology - Ep 3.4
    Part 2 - Metabolism in hematology - Ep 3.4 29.07.2025 28m
    In this second part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology, particularly focusing on #AML. They discuss the challenges and advancements in metabolomics, the importance of integrating multi-omics approaches, and the future directions of research in this field. The conversation highlights the need for a deeper understanding of metabolic pathways and their implications for cancer treatment, emphasizing the significance of context in cellular behavior and the potential...
  • Part 1 - Metabolism in hematology - Ep 3.4
    Part 1 - Metabolism in hematology - Ep 3.4 29.07.2025 29m
    In this 2-part episode of the HemaSphere podcast, host Dr Charles de Bock and guests Dr Jörg Büscher and Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology and cancer research. The discussion highlights the technological advancements in metabolic analysis and their impact on understanding cellular metabolism. They also explore the challenges and future directions in metabolism research and the potential of spatial metabolomics."Metabolism in hematology”, is on our website, all major podcast platforms, and YouTube. Li...
  • Machine learning for AML-MRD - Ep 3.3
    Machine learning for AML-MRD - Ep 3.3 02.07.2025 29m
    In this episode of the HemaSphere podcast, host Charles de Bock and guest Tim Mocking, PhD, discuss the role of machine learning in the assessment of measurable residual disease (MRD) in acute myeloid leukemia (AML). They explore the challenges of MRD detection, the potential of machine learning to improve accuracy and efficiency, and the importance of understanding the human element in computational methods. The conversation also touches on the adoption of AI in hematology, the future of flow cytometry, and the implications of new technologies for patient care.Episode 3.3 - Machine learning f...
  • 2 of 2: Navigating Neutropenia: New Guidelines Explained - Ep 3.2
    2 of 2: Navigating Neutropenia: New Guidelines Explained - Ep 3.2 03.06.2025 28m
    In this episode of the HemaSphere podcast, host Dr Charles De Bock discusses the newly published Guidelines on the treatment of neutropenias with co-authors Dr. Francesca Fioredda and Dr. Eleni Papadaki. They explore the importance of these international guidelines, the challenges faced in gathering evidence, and the consensus-building process among experts. The conversation also delves into treatment options, including gene therapy and stem cell transplants, while highlighting the need for more research in the field."European guidelines on treatment and supportive measures in chronic neutrope...
  • Single‐cell DNA and surface protein - Ep 3.1
    Single‐cell DNA and surface protein - Ep 3.1 06.05.2025 34m
    In this episode of the HemaSphere podcast, host Charles De Bock engages with HemaSphere Editor in Chief Professor Jan Cools, Professor Heidi Segers, and Doctor Margo Aertgeerts to discuss their recent study on acute lymphoblastic leukemia (ALL). They explore the advancements in treatment, particularly for high-hyperdiploid ALL, the challenges of relapse, and the innovative use of single cell sequencing to uncover insights into genetic mutations and clonal composition. The conversation delves into the implications of RAS mutations, the technical challenges of analyzing rare cell populations, an...
  • Two distinct fetal-type signatures characterize JMML - Ep 2.8
    Two distinct fetal-type signatures characterize JMML - Ep 2.8 02.04.2025 36m
    In this episode of the HemaSphere podcast, host Charles de Bock engages with Professor Hélène Cavé and Dr. Marion Strullu to discuss their recent study on juvenile myelomonocytic leukemia (JMML). They delve into the complexities of diagnosing JMML, the genetic mutations associated with the disease, and the prognostic factors that influence patient outcomes. The conversation explores the intriguing biology of JMML, including the role of transcriptional signatures and methylation patterns, as well as the challenges faced in sample collection. The episode concludes with insights into future resea...
  • Revolutionizing Pediatric Cancer Research with PDXs - Ep 2.7
    Revolutionizing Pediatric Cancer Research with PDXs - Ep 2.7 06.02.2025 35m
    In this episode of the HemaSphere podcast, host Dr Charles de Bock discusses the critical role of mouse models in understanding leukemogenesis and hematopoiesis with Prof Richard Lock. They explore the significance of patient-derived xenografts (PDXs) in preclinical testing, the challenges faced in generating PDXs for acute myeloid leukemia (AML), and the importance of molecular characterization. The conversation also covers the objective response criteria in drug testing, the innovative single mouse trial approach, and the future of immunotherapy testing in PDX models. Revolutionizing Pediatr...
  • High 5hmC predicts worse OS - Ep 2.6
    High 5hmC predicts worse OS - Ep 2.6 07.01.2025 25m
    In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discus...
  • Informed consent is almost impossible - Ep 2.5
    Informed consent is almost impossible - Ep 2.5 27.11.2024 39m
    This podcast episode delves into the complexities of informed consent in healthcare, particularly in the context of hematology. The discussion with host Dr Charles de Bock features insights from Dr Stephen Hibbs and Dr Louise Caldwell, authors of the HemaTopics "Informed consent is almost impossible” and guest Mark Dawson, a patient family member, exploring the emotional, legal, and ethical dimensions of consent. Key themes include the variability of consent across jurisdictions, the impact of time pressures on communication, and the importance of trust in the clinician-patient relationship. T...
  • Best of Pediatric Hematology from EHA2024 - Ep 2.4
    Best of Pediatric Hematology from EHA2024 - Ep 2.4 25.10.2024 42m
    In the latest episode, Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan. “Best of Pediatric Hematology from EHA2024”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enj...

Popular in

The podcast also appears in the podcast charts of these countries.